Search This Blog

Tuesday, June 25, 2019

Bausch Health’s DUOBRII lotion now available in U.S.; shares up 4% premarket

Bausch Health Companies (NYSE:BHC) has launched DUOBRII (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% in U.S. for patients with plaque psoriasis.
The FDA approved DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation.
DUOBRII Lotion is priced at $825 for a a 100-gram tube.
Shares are up 4% premarket

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.